Orteronel

Orteronel
IUPAC name 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide
Other names TAK-700
Identifiers
CAS number	566939-85-3 Y
PubChem	9883029
ChemSpider	8058704
UNII	UE5K2FNS92
Jmol-3D images	Image 1
SMILES O=C(NC)c2ccc1cc(ccc1c2)C4(O)c3cncn3CC4
InChI InChI=InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)
Properties
Molecular formula	C18H17N3O2
Molar mass	307.35 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Orteronel (TAK-700) is an experimental drug for the treatment of cancer under development by Millennium Pharmaceuticals.^[1] It is currently in Phase III clinical trials for metastatic, hormone-refractory prostate cancer.^[2]

Orteronel is an inhibitor of the enzyme CYP17A1.^[3]

References

1. ^ Millennium and Takeda Announce Advancement of Prostate Cancer Program, Millennium Pharmaceuticals
2. ^ TAK-700, ClinicalTrials.gov
3. ^ New Drugs Online Report for Orteronel, UK Medicines Information, National Health Service